Understanding the challenge of comparative effectiveness research in focal epilepsy: A review of network meta‐analyses and real‐world evidence on antiepileptic drugs-Reference-Cited by-同舟云学术

Understanding the challenge of comparative effectiveness research in focal epilepsy: A review of network meta‐analyses and real‐world evidence on antiepileptic drugs

Published:2020-03-22 Issue:4 Volume:61 Page:595-609
ISSN:0013-9580
Container-title:Epilepsia
language:en
Short-container-title:Epilepsia

Author:

Thieffry Solène¹^ORCID,Klein Pavel²³^ORCID,Baulac Michel⁴,Plumb Jonathan¹,Pelgrims Barbara¹,Steeves Sara⁵^ORCID,Borghs Simon⁶^ORCID

Affiliation:

1. UCB Pharma Brussels Belgium

2. Mid‐Atlantic Epilepsy and Sleep Center Bethesda Maryland

3. Department of Neurology The George Washington University Washington District of Columbia

4. Department of Neurology, Pitié‐Salpêtrière Hospital & ICM (Brain & Spine Institute) Sorbonne University Paris France

5. Costello Medical Cambridge UK

6. UCB Pharma Slough UK

Funder

UCB Pharma

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/epi.16476

Reference53 articles.

1. NICE.Guide to the methods of technology appraisal 2013.2013[cited 2020 Mar 05]. Available fromhttps://www.nice.org.uk/process/pmg9/chapter/the‐reference‐case#synthesis‐of‐evidence‐on‐health‐effects

2. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports

3. A Comparison of National Guidelines for Network Meta-Analysis

4. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy

5. Challenges in the clinical development of new antiepileptic drugs

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Balancing ethical norms and duties for the introduction of new medicines through conditional marketing authorization: a research agenda;Frontiers in Medicine;2024-06-24

2. Mirror, Mirror on the Wall, Who’s the Fairest Third Generation Anti-Seizure Medication of All?;Epilepsy Currents;2024-02-20

3. Methodological review of NMA bias concepts provides groundwork for the development of a list of concepts for potential inclusion in a new risk of bias tool for network meta-analysis (RoB NMA Tool);Systematic Reviews;2024-01-12

4. A real‐world comparison among third‐generation antiseizure medications: Results from the COMPARE study;Epilepsia;2023-12-16

5. Letter: Comparing first‐line infliximab and vedolizumab for ulcerative colitis—it depends on how you use the drug. Authors' reply;Alimentary Pharmacology & Therapeutics;2023-11-04